<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820101</url>
  </required_header>
  <id_info>
    <org_study_id>DEXLISA 920/CE Marca</org_study_id>
    <nct_id>NCT04820101</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for LISA Procedure in Preterm Infants</brief_title>
  <acronym>DEXLISA</acronym>
  <official_title>Dexmedetomidine for LISA Procedure in Preterm Infants: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate: the effectiveness of dexmedetomidine for analgesia and&#xD;
      sedation during LISA procedure, without compromising the respiratory drive; the safety of&#xD;
      this drug on the preterm infant in a pilot study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information will be given to parents of preterm babies &lt;36 wGA upon their admission to the&#xD;
      NICU (neonatal intensive care unit), and informed consent will be obtained as soon as&#xD;
      possible. Eligible babies for LISA procedure (dyspneic and FiO2 &gt; 0.30 on CPAP pressure of at&#xD;
      least 6 cmH2O) undergo sedation with dexmedetomidine 1 mcg/kg, administered slowly iv in 10&#xD;
      minutes, together with non pharmacological techniques. After the step of sedation LISA is&#xD;
      performed. Before/during and after the procedure pain will be assessed by the NIPS scale and&#xD;
      the quality of intubation will be evaluated; then other events related to the procedure will&#xD;
      be strictly collected for the first 24 hours. Babies will then be managed in usual NICU way&#xD;
      and clinical data will be unregistered on respiratory, neurological and hemodynamic outcomes&#xD;
      during the hospital stay, and especially at discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effectiveness of dexmedetomidine in achieving sedation for LISA procedure</measure>
    <time_frame>basal (before procedure), during and immediately after the procedure</time_frame>
    <description>evaluation of changes in Neonatal Infant Pain Scale (NIPS) score (0-2 points= no pain, 3-4 points = moderate pain; &gt; 4 = severe pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of dexmedetomidine in sedating preterm infants</measure>
    <time_frame>24 hours</time_frame>
    <description>evaluation of number of apneas ( &gt; 20 seconds or &lt; 20 seconds with bradycardia &lt; 100 bpm or desaturation ( SpO2 &lt; 85%)); number of severe apnea and bradycardia (defined by the American Academy of Pediatrics Guidelines as apnea &gt; 30 seconds and/or heart rate &lt; 60 beats/minute for more than 10 seconds); need for intubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of laryngoscopies needed to perform LISA</measure>
    <time_frame>during the procedure</time_frame>
    <description>calculate the number of laryngoscopies needed to perform LISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time needed to perform LISA</measure>
    <time_frame>during the procedure</time_frame>
    <description>calculate the time needed to perform LISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation conditions</measure>
    <time_frame>during the procedure</time_frame>
    <description>evaluated by the operator using the Goldberg scale (3 = excellent intubation conditions; 4-6= good intubation conditions; 7-9 = poor intubation conditions; 10-12 = inadequate intubation conditions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evolution of cardiorespiratory parameters</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>heart rate (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evolution of cardiorespiratory parameters</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>respiratory rate (breaths per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evolution of cardiorespiratory parameters</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evolution of cardiorespiratory parameters</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evolution of cardiorespiratory parameters</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>FiO2 maxima during the procedure maintained for at least 30 seconds (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in ventilation mode</measure>
    <time_frame>1 min, 3 min, 5 min, 15 min, 30 min, 60 min and 120 min after the first drug injection</time_frame>
    <description>inspiratory and end-expiratory ventilation pressures changes (cmH2O)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of drug adverse effects</measure>
    <time_frame>24 hours after drug injection</time_frame>
    <description>respiratory events (i.e. bronchospasm) or cardiovascular events (bradycardia, hypotension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of pneumothorax or selective administration of surfactant</measure>
    <time_frame>24 hours after drug injection</time_frame>
    <description>RX evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes</measure>
    <time_frame>at 40 weeks PMA</time_frame>
    <description>mortality (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes</measure>
    <time_frame>at 40 weeks PMA</time_frame>
    <description>bronchopulmonary dysplasia (%), defined as oxygen administration and/or respiratory support at 36 wGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes</measure>
    <time_frame>at 40 weeks PMA</time_frame>
    <description>intraventricular hemorrhage (%) and periventricular leukomalacia (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes</measure>
    <time_frame>at 40 weeks PMA</time_frame>
    <description>necrotizing enterocolitis (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes</measure>
    <time_frame>at 40 weeks PMA</time_frame>
    <description>retinopathy of prematurity (%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>RDS</condition>
  <arm_group>
    <arm_group_label>Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure</description>
    <arm_group_label>Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy</arm_group_label>
    <other_name>LISA procedure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Preterm newborns between 26+0 and 36+6 weeks of gestation stratified in two groups:&#xD;
             VLBWI 26-31+6and LBWI 32-36+6.&#xD;
&#xD;
          2. Respiratory distress syndrome requiring surfactant therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need for emergency intubation in the delivery room&#xD;
&#xD;
          2. Major congenital malformations (such as cardiopathies)&#xD;
&#xD;
          3. Chromosomic abnormalities&#xD;
&#xD;
          4. Fetal Hydrops&#xD;
&#xD;
          5. Hypercapnia: CO2 &gt; 65 mmHg&#xD;
&#xD;
          6. Pneumothorax&#xD;
&#xD;
          7. Hemodynamic compromise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Lago, MD</last_name>
    <phone>00390422322608</phone>
    <email>paola.lago@aulss2.veneto.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice Galeazzo, MD</last_name>
    <phone>00390422322608</phone>
    <email>beatrice.galeazzo@aulss2.veneto.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Paola Lago</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Beatrice c Galeazzo, MD</last_name>
      <phone>00390422322608</phone>
      <email>beatrice.galeazzo@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Paola Lago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Galeazzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Battajon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Favero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Vendramin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sánchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. doi: 10.1056/NEJMoa0911783. Epub 2010 May 16. Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235.</citation>
    <PMID>20472939</PMID>
  </reference>
  <reference>
    <citation>Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev. 2016 Dec 15;12:CD005384. doi: 10.1002/14651858.CD005384.pub2. Review.</citation>
    <PMID>27976361</PMID>
  </reference>
  <reference>
    <citation>Fischer HS, Bührer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2013 Nov;132(5):e1351-60. doi: 10.1542/peds.2013-1880. Epub 2013 Oct 21. Review.</citation>
    <PMID>24144716</PMID>
  </reference>
  <reference>
    <citation>Jensen EA, DeMauro SB, Kornhauser M, Aghai ZH, Greenspan JS, Dysart KC. Effects of Multiple Ventilation Courses and Duration of Mechanical Ventilation on Respiratory Outcomes in Extremely Low-Birth-Weight Infants. JAMA Pediatr. 2015 Nov;169(11):1011-7. doi: 10.1001/jamapediatrics.2015.2401.</citation>
    <PMID>26414549</PMID>
  </reference>
  <reference>
    <citation>Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, et al. [Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study]. Ugeskr Laeger. 1992 Jul 27;154(31):2136-9. Danish.</citation>
    <PMID>1509593</PMID>
  </reference>
  <reference>
    <citation>Kribs A. Minimally Invasive Surfactant Therapy and Noninvasive Respiratory Support. Clin Perinatol. 2016 Dec;43(4):755-771. doi: 10.1016/j.clp.2016.07.010. Epub 2016 Oct 14. Review.</citation>
    <PMID>27837757</PMID>
  </reference>
  <reference>
    <citation>Kribs A, Roll C, Göpel W, Wieg C, Groneck P, Laux R, Teig N, Hoehn T, Böhm W, Welzing L, Vochem M, Hoppenz M, Bührer C, Mehler K, Stützer H, Franklin J, Stöhr A, Herting E, Roth B; NINSAPP Trial Investigators. Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2015 Aug;169(8):723-30. doi: 10.1001/jamapediatrics.2015.0504.</citation>
    <PMID>26053341</PMID>
  </reference>
  <reference>
    <citation>Isayama T, Iwami H, McDonald S, Beyene J. Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2016 Aug 9;316(6):611-24. doi: 10.1001/jama.2016.10708. Review. Erratum in: JAMA. 2016 Sep 13;316(10):1116.</citation>
    <PMID>27532916</PMID>
  </reference>
  <reference>
    <citation>Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2017 Jan;102(1):F17-F23. doi: 10.1136/archdischild-2015-310299. Epub 2016 Nov 15. Review.</citation>
    <PMID>27852668</PMID>
  </reference>
  <reference>
    <citation>Kumar P, Denson SE, Mancuso TJ; Committee on Fetus and Newborn, Section on Anesthesiology and Pain Medicine. Premedication for nonemergency endotracheal intubation in the neonate. Pediatrics. 2010 Mar;125(3):608-15. doi: 10.1542/peds.2009-2863. Epub 2010 Feb 22. Review.</citation>
    <PMID>20176672</PMID>
  </reference>
  <reference>
    <citation>COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE. Prevention and Management of Procedural Pain in the Neonate: An Update. Pediatrics. 2016 Feb;137(2):e20154271. doi: 10.1542/peds.2015-4271. Epub 2016 Jan 25.</citation>
    <PMID>26810788</PMID>
  </reference>
  <reference>
    <citation>Foglia EE, Ades A, Sawyer T, Glass KM, Singh N, Jung P, Quek BH, Johnston LC, Barry J, Zenge J, Moussa A, Kim JH, DeMeo SD, Napolitano N, Nadkarni V, Nishisaki A; NEAR4NEOS Investigators. Neonatal Intubation Practice and Outcomes: An International Registry Study. Pediatrics. 2019 Jan;143(1). pii: e20180902. doi: 10.1542/peds.2018-0902. Epub 2018 Dec 11.</citation>
    <PMID>30538147</PMID>
  </reference>
  <reference>
    <citation>Descamps CS, Chevallier M, Ego A, Pin I, Epiard C, Debillon T. Propofol for sedation during less invasive surfactant administration in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2017 Sep;102(5):F465. doi: 10.1136/archdischild-2017-312791. Epub 2017 May 8.</citation>
    <PMID>28483817</PMID>
  </reference>
  <reference>
    <citation>Dekker J, Lopriore E, Rijken M, Rijntjes-Jacobs E, Smits-Wintjens V, Te Pas A. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2016;109(4):308-13. doi: 10.1159/000443823. Epub 2016 Feb 24.</citation>
    <PMID>26907795</PMID>
  </reference>
  <reference>
    <citation>Bourgoin L, Caeymaex L, Decobert F, Jung C, Danan C, Durrmeyer X. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. Acta Paediatr. 2018 Jul;107(7):1184-1190. doi: 10.1111/apa.14317. Epub 2018 Apr 16.</citation>
    <PMID>29532502</PMID>
  </reference>
  <reference>
    <citation>Dekker J, Lopriore E, van Zanten HA, Tan RNGB, Hooper SB, Te Pas AB. Sedation during minimal invasive surfactant therapy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019 Jul;104(4):F378-F383. doi: 10.1136/archdischild-2018-315015. Epub 2018 Aug 1.</citation>
    <PMID>30068669</PMID>
  </reference>
  <reference>
    <citation>Chevallier M, Durrmeyer X, Ego A, Debillon T; PROLISA Study Group. Propofol versus placebo (with rescue with ketamine) before less invasive surfactant administration: study protocol for a multicenter, double-blind, placebo controlled trial (PROLISA). BMC Pediatr. 2020 May 8;20(1):199. doi: 10.1186/s12887-020-02112-x.</citation>
    <PMID>32384914</PMID>
  </reference>
  <reference>
    <citation>Venkatraman R, Hungerford JL, Hall MW, Moore-Clingenpeel M, Tobias JD. Dexmedetomidine for Sedation During Noninvasive Ventilation in Pediatric Patients. Pediatr Crit Care Med. 2017 Sep;18(9):831-837. doi: 10.1097/PCC.0000000000001226.</citation>
    <PMID>28598946</PMID>
  </reference>
  <reference>
    <citation>Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet. 2017 Aug;56(8):893-913. doi: 10.1007/s40262-017-0507-7. Review.</citation>
    <PMID>28105598</PMID>
  </reference>
  <reference>
    <citation>Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C. The development of a tool to assess neonatal pain. Neonatal Netw. 1993 Sep;12(6):59-66.</citation>
    <PMID>8413140</PMID>
  </reference>
  <reference>
    <citation>Wyckoff MH, Aziz K, Escobedo MB, Kapadia VS, Kattwinkel J, Perlman JM, Simon WM, Weiner GM, Zaichkin JG. Part 13: Neonatal Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015 Nov 3;132(18 Suppl 2):S543-60. doi: 10.1161/CIR.0000000000000267. Review.</citation>
    <PMID>26473001</PMID>
  </reference>
  <reference>
    <citation>Tran DTT, Newton EK, Mount VAH, Lee JS, Mansour C, Wells GA, Perry JJ. Rocuronium vs. succinylcholine for rapid sequence intubation: a Cochrane systematic review. Anaesthesia. 2017 Jun;72(6):765-777. doi: 10.1111/anae.13903.</citation>
    <PMID>28654173</PMID>
  </reference>
  <reference>
    <citation>Eichenwald EC; Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of Prematurity. Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-3757. Epub 2015 Dec 1.</citation>
    <PMID>26628729</PMID>
  </reference>
  <results_reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11.</citation>
    <PMID>30974433</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Paola Lago</investigator_full_name>
    <investigator_title>Head of Neonatal Intensive Care Unit, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RDS</keyword>
  <keyword>LISA</keyword>
  <keyword>preterm</keyword>
  <keyword>sedation</keyword>
  <keyword>dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>at the end of the study (April 2023)</ipd_time_frame>
    <ipd_access_criteria>The investigators will access the data and the statistician</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

